Publications by authors named "Guillermo Garcia-Manero"

100Publications

Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management.

Am J Hematol 2020 Aug 3. Epub 2020 Aug 3.

Section of MDS, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25950DOI Listing
August 2020

Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.

Mediterr J Hematol Infect Dis 2020 1;12(1):e2020044. Epub 2020 Jul 1.

Department of Infectious Diseases, Infection Control and Employee Health. The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2020.044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340251PMC
July 2020

MDS/MPN-RS-T justified inclusion as a unique disease entity?

Best Pract Res Clin Haematol 2020 06 17;33(2):101147. Epub 2020 Jan 17.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2020.101147DOI Listing
June 2020

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.

Leuk Res 2020 Jul 12;94:106369. Epub 2020 May 12.

Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106369DOI Listing
July 2020

Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.

Clin Lymphoma Myeloma Leuk 2020 Sep 20;20(9):e597-e605. Epub 2020 Mar 20.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.03.005DOI Listing
September 2020

t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?

Ann Hematol 2020 Mar 31;99(3):487-500. Epub 2020 Jan 31.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0072, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-03909-7DOI Listing
March 2020

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

N Engl J Med 2020 01;382(2):140-151

From Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire (CHU) de Lille, Lille (B.Q.), the Department of Internal Medicine, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse (O.B.-R.), and Université Cote d'Azur, Département d'Hématologie Clinique, CHU Nice, Nice (T.C.) - all in France; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig (U.P.), Klinik für Hämatologie, Onkologie, and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf (U.G.), and Klinik und Poliklinik für Innere Medizin III, Technische Universität München, Munich (K.S.G.) - all in Germany; the Department of Haemato-Oncology, King's College London, London (G.J.M.), Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford (P.V.), and the Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds (D.B.) - all in the United Kingdom; the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.G.-M.); Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (R.B.); MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence (V.S.), the Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna (C.F.), the University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia (M.C.), the Hematology Unit, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria (F.S., V.G.), and Dipartimento Biomedicina e Prevenzione, University of Rome Tor Vergata, Rome (M.-T.V.) - all in Italy; the Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca (M.D.-C.), Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville (J.F.F.), and the Department of Hematology, Hospital Universitario Cruces, Vizcaya (B.A.) - all in Spain; the Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey (O.I.); the Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland (M.A.S.); the Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges (D.S.), and Universitair Ziekenhuis Gent, Ghent (D.M.) - both in Belgium; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (A.E.D.); the Division of Hematology-Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (J.G.J.), and Albert Einstein College of Medicine (A.V.) - both in New York; the Department of Hematology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands (E.V.); Stanford University Cancer Center, Stanford, CA (P.L.G.); the Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm (E.H.-L.); the Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT (A.M.Z.); Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville (M.R.S.); Celgene, Summit, NJ (A.L., J.Z., A.R., D.R.D.); Celgene International, Boudry, Switzerland (A.B.); Acceleron Pharma, Cambridge, MA (P.G.L., M.L.S.); and Moffitt Cancer Center, Tampa, FL (R.S.K., A.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908892DOI Listing
January 2020

Highlights in Myelodysplastic Syndromes From the 60th American Society of Hematology Annual Meeting: Commentary.

Clin Adv Hematol Oncol 2019 02;17 Suppl 5(2):16-19

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
February 2019

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Am J Hematol 2020 02 29;95(2):227-229. Epub 2019 Aug 29.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25610DOI Listing
February 2020

Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.

Theranostics 2019 31;9(13):3768-3779. Epub 2019 May 31.

Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.34327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587355PMC
September 2020

Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes.

Stat Methods Med Res 2020 Apr 7;29(4):1181-1196. Epub 2019 Jun 7.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0962280219852721
Publisher Site
http://dx.doi.org/10.1177/0962280219852721DOI Listing
April 2020

Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.

Cancer Commun (Lond) 2019 04 4;39(1):17. Epub 2019 Apr 4.

Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40880-019-0362-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449955PMC
April 2019

The role of TGFβ in hematopoiesis and myeloid disorders.

Leukemia 2019 05 28;33(5):1076-1089. Epub 2019 Feb 28.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0420-1DOI Listing
May 2019

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Cancer 2018 12 5;124(24):4601-4609. Epub 2018 Oct 5.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31769
Publisher Site
http://dx.doi.org/10.1002/cncr.31769DOI Listing
December 2018

Improving Prognostic Tools for Patients With Myelodysplastic Syndromes.

Mayo Clin Proc 2018 10;93(10):1340-1342

Section of MDS, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2018.08.025DOI Listing
October 2018